Eli Lilly and Novo Nordisk are facing scrutiny regarding their name-brand weight loss drugs due to findings during an FDA data review.
1 report, 1 independent
Updated Jun 12
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Eli Lilly and Novo Nordisk are facing scrutiny regarding their name-brand weight loss drugs due to findings during an FDA data review.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Eli Lilly and Novo Nordisk are pushing for claims-level patient data submission.Sub-event
- Eli Lilly and Novo Nordisk products are currently awaiting necessary approval from the Food and Drug Administration.Sub-event
Review of FDA data reveals medication errors in the name-brand weight loss drugs manufactured by Eli Lilly and Novo Nordisk.1 source
Keep exploring
The entities involved
-
Eli Lilly and Company
American pharmaceutical company
-
Novo Nordisk
Danish pharmaceutical company
-
Food and Drug Administration
government organization in Nonthaburi, Thailand
Related events
- Eli Lilly and Novo Nordisk are competing for market share in the weight loss drug sector.
- Lilly and Novo Nordisk are competing in the weight loss drug market, with Lilly expanding its US market coverage.
- Novo Nordisk and Eli Lilly are utilizing physician networks in Texas, including Carlos Campos, to promote their weight-loss drugs.
- Eli Lilly and Novo Nordisk have both developed anti-obesity drugs, intensifying competition in the weight loss market.
- Major pharmaceutical companies, including Viking Therapeutics, Eli Lilly, and Novo Nordisk, are advancing their weight loss drug pipelines.